Barclays analyst Luke Sergott raised the firm’s price target on Charles River (CRL) to $210 from $200 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River initiated with an Outperform at RBC Capital
- Charles River price target lowered to $160 from $165 at JPMorgan
- Charles River added to ‘Tactical Outperform’ list at Evercore ISI
- Charles River: Portfolio Reshaping Improves Margins but Lowers Growth, Supporting Hold Rating
- Sharpened Focus and Strategic Divestitures Underpin Buy Rating on Charles River Amid Valuation Discount